landiolol
AssetAlso AOP-200704, LDLL-600, ONO-1101, SIBBORAN
Selectively blocks beta-1 adrenergic receptors to rapidly reduce ventricular rate.
- Stage
- Approved
- Modality
- Small molecule
- Target
- ADRB1
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Supraventricular tachycardia
Approved, newsfilecorp.com, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Evidence for its targets1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.